Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law”
Hospital group 340B Health yesterday swung back hard against a congressional watchdog agency’s recommendations for stricter federal policing of 340B duplicate discounts, calling them “misguided, unworkable, and contrary to federal law.”
Yesterday, in its second major report on the 340B program this month, the Government Accountability Office (GAO) said “limitations” in federal oversight of 340B and the Medicaid Drug Rebate Program (MDRP) increase the risk that drug companies are being forced to pay 340B discounts and Medicaid rebates on the same drugs. GAO focused on duplicate discounts and rebates on drugs dispensed to Medicaid managed care (MCO) beneficiaries. It said the Health Resources and Services Administration (HRSA), which oversees 340B, should incorporate 340B covered entities’ compliance with state policies into its audits, and require covered entities to work with manufacturers regarding repayment of identified duplicate discounts in managed care.
Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law” Hospital group 340B Health yesterday swung back hard against a congressional watchdog agency’s recommendations for stricter federal policing of 340B duplicate discounts, calling them “misguided, unworkable, and contrary to […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
